nafamostat has been researched along with Hepatocellular Carcinoma in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 8.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC)." | 4.12 | Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure. ( Cho, JY; Han, HS; Jo, Y; Kim, M; Lee, B; Lee, HW; Lee, JS; Yoon, YS, 2022) |
| "The effect of nafamostat mesilate on coagulation and fibrinolysis was investigated in a study of 22 patients with hepatocellular carcinoma who underwent a hepatic resection." | 3.69 | Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection. ( Kamakura, T; Matsumata, T; Shimada, M; Shirabe, K; Sugimachi, K; Taketomi, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, B | 1 |
| Cho, JY | 1 |
| Han, HS | 1 |
| Yoon, YS | 1 |
| Lee, HW | 1 |
| Lee, JS | 1 |
| Kim, M | 1 |
| Jo, Y | 1 |
| Shimada, M | 1 |
| Matsumata, T | 1 |
| Shirabe, K | 1 |
| Kamakura, T | 1 |
| Taketomi, A | 1 |
| Sugimachi, K | 1 |
2 other studies available for nafamostat and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Benzamidines; Bilirubin; Carcinoma, Hepatocellula | 2022 |
Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
Topics: Aged; Antifibrinolytic Agents; Benzamidines; Blood Coagulation; Blood Loss, Surgical; Carcinoma, Hep | 1994 |